• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿科肿瘤学中的液体活检:机遇与挑战。

Liquid biopsies in pediatric oncology: opportunities and obstacles.

机构信息

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

出版信息

Curr Opin Pediatr. 2022 Feb 1;34(1):39-47. doi: 10.1097/MOP.0000000000001088.

DOI:10.1097/MOP.0000000000001088
PMID:34840249
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8727502/
Abstract

PURPOSE OF REVIEW

Liquid biopsies have emerged as a noninvasive alternative to tissue biopsy with potential applications during all stages of pediatric oncology care. The purpose of this review is to provide a survey of pediatric cell-free DNA (cfDNA) studies, illustrate their potential applications in pediatric oncology, and to discuss technological challenges and approaches to overcome these hurdles.

RECENT FINDINGS

Recent literature has demonstrated liquid biopsies' ability to inform treatment selection at diagnosis, monitor clonal evolution during treatment, sensitively detect minimum residual disease following local control, and provide sensitive posttherapy surveillance. Advantages include reduced procedural anesthesia, molecular profiling unbiased by tissue heterogeneity, and ability to track clonal evolution. Challenges to wider implementation in pediatric oncology, however, include blood volume restrictions and relatively low mutational burden in childhood cancers. Multiomic approaches address challenges presented by low-mutational burden, and novel bioinformatic analyses allow a single assay to yield increasing amounts of information, reducing blood volume requirements.

SUMMARY

Liquid biopsies hold tremendous promise in pediatric oncology, enabling noninvasive serial surveillance with adaptive care. Already integrated into adult care, recent advances in technologies and bioinformatics have improved applicability to the pediatric cancer landscape.

摘要

目的综述

液体活检作为组织活检的一种非侵入性替代方法已经出现,具有在儿科肿瘤治疗的所有阶段应用的潜力。本文的目的是对儿科游离 DNA(cfDNA)的研究进行综述,说明其在儿科肿瘤学中的潜在应用,并讨论克服这些障碍的技术挑战和方法。

最近的发现

最近的文献表明,液体活检能够在诊断时提供治疗选择信息,在治疗过程中监测克隆进化,灵敏地检测局部控制后的微小残留疾病,并进行敏感的治疗后监测。其优点包括减少程序麻醉、不受组织异质性影响的分子分析,以及能够跟踪克隆进化。然而,在儿科肿瘤学中广泛应用的挑战包括血量限制和儿童癌症中相对较低的突变负担。多组学方法解决了低突变负担带来的挑战,而新型生物信息学分析允许单次检测产生越来越多的信息,从而减少了血量需求。

总结

液体活检在儿科肿瘤学中具有巨大的潜力,能够进行非侵入性的连续监测和适应性治疗。液体活检已经整合到成人护理中,最近技术和生物信息学的进步提高了其在儿科癌症领域的适用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f674/8728684/319948900e39/coped-34-39-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f674/8728684/7ee6133aa4d2/coped-34-39-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f674/8728684/113d4058ba08/coped-34-39-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f674/8728684/319948900e39/coped-34-39-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f674/8728684/7ee6133aa4d2/coped-34-39-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f674/8728684/113d4058ba08/coped-34-39-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f674/8728684/319948900e39/coped-34-39-g003.jpg

相似文献

1
Liquid biopsies in pediatric oncology: opportunities and obstacles.儿科肿瘤学中的液体活检:机遇与挑战。
Curr Opin Pediatr. 2022 Feb 1;34(1):39-47. doi: 10.1097/MOP.0000000000001088.
2
The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review.液体活检在儿童实体瘤诊断和治疗中的陷阱和前景:综述。
Eur J Pediatr. 2020 Feb;179(2):191-202. doi: 10.1007/s00431-019-03545-y. Epub 2020 Jan 3.
3
Liquid biopsy and its role in an advanced clinical trial for lung cancer.液体活检及其在肺癌晚期临床试验中的作用。
Exp Biol Med (Maywood). 2018 Feb;243(3):262-271. doi: 10.1177/1535370217750087.
4
How liquid biopsies can change clinical practice in oncology.液体活检如何改变肿瘤学的临床实践。
Ann Oncol. 2019 Oct 1;30(10):1580-1590. doi: 10.1093/annonc/mdz227.
5
Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring.液体活检:癌症诊断和监测的应用。
Genes (Basel). 2021 Feb 27;12(3):349. doi: 10.3390/genes12030349.
6
Recent Advances in Blood-Based Liquid Biopsy Approaches in Prostate Cancer.基于血液的液体活检在前列腺癌中的最新进展。
Cancer J. 2023;29(4):220-225. doi: 10.1097/PPO.0000000000000672.
7
Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA.游离 DNA 甲基化生物标志物的液体活检。
Trends Mol Med. 2021 May;27(5):482-500. doi: 10.1016/j.molmed.2020.12.011. Epub 2021 Jan 23.
8
Liquid biopsy: current technology and clinical applications.液体活检:当前技术与临床应用。
J Hematol Oncol. 2022 Sep 12;15(1):131. doi: 10.1186/s13045-022-01351-y.
9
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.液体活检能否通过低深度全基因组测序检测肉瘤患者的循环肿瘤DNA?一项初步评估。
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
10
Diagnosis of pediatric central nervous system tumors using methylation profiling of cfDNA from cerebrospinal fluid.利用脑脊液 cfDNA 的甲基化谱诊断小儿中枢神经系统肿瘤。
Clin Epigenetics. 2024 Jul 5;16(1):87. doi: 10.1186/s13148-024-01696-w.

引用本文的文献

1
A First-in-Class High-Throughput Screen to Discover Modulators of the Alternative Lengthening of Telomeres (ALT) Pathway.一种用于发现端粒替代延长(ALT)途径调节剂的首创高通量筛选方法。
ACS Pharmacol Transl Sci. 2024 Aug 13;7(9):2799-2819. doi: 10.1021/acsptsci.4c00251. eCollection 2024 Sep 13.
2
A comprehensive overview of liquid biopsy applications in pediatric solid tumors.液体活检在儿科实体瘤中的应用综述
NPJ Precis Oncol. 2024 Aug 3;8(1):172. doi: 10.1038/s41698-024-00657-z.
3
Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.

本文引用的文献

1
Retrospective Evaluation of Somatic Alterations in Cell-Free DNA from Blood in Retinoblastoma.视网膜母细胞瘤患者血液中游离DNA体细胞改变的回顾性评估
Ophthalmol Sci. 2021 Mar 16;1(1):100015. doi: 10.1016/j.xops.2021.100015. eCollection 2021 Mar.
2
Clonal Hematopoiesis of Indeterminate Potential: an Expanding Genetic Cause of Cardiovascular Disease.克隆性造血:心血管疾病不断扩展的遗传病因。
Curr Atheroscler Rep. 2021 Sep 1;23(11):66. doi: 10.1007/s11883-021-00966-9.
3
Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.
使用游离 DNA 片段组学早期检测恶性和癌前周围神经肿瘤。
Clin Cancer Res. 2024 Oct 1;30(19):4363-4376. doi: 10.1158/1078-0432.CCR-24-0797.
4
Insights into Personalized Care Strategies for Wilms Tumor: A Narrative Literature Review.肾母细胞瘤个性化护理策略的见解:一篇叙述性文献综述
Biomedicines. 2024 Jun 30;12(7):1455. doi: 10.3390/biomedicines12071455.
5
Contemporary Approach to Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.当代神经纤维瘤病 1 型相关恶性外周神经鞘瘤治疗方法。
Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e432242. doi: 10.1200/EDBK_432242.
6
Early detection of malignant and pre-malignant peripheral nerve tumors using cell-free DNA fragmentomics.利用游离DNA片段组学早期检测恶性和癌前周围神经肿瘤
medRxiv. 2024 Mar 11:2024.01.18.24301053. doi: 10.1101/2024.01.18.24301053.
7
Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials.神经纤维瘤病和雪旺细胞瘤临床试验中生物标志物分析用生物样本采集和注释的推荐意见。
Clin Trials. 2024 Feb;21(1):40-50. doi: 10.1177/17407745231203330. Epub 2023 Oct 31.
8
Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma.胰岛素样生长因子 1 受体和 Src 家族激酶 YES 的双重靶向药物 Ganitumab 联合 Dasatinib 的 I 期临床试验用于横纹肌肉瘤。
Clin Cancer Res. 2023 Sep 1;29(17):3329-3339. doi: 10.1158/1078-0432.CCR-23-0709.
9
Circulating Cell-Free Tumor Deoxyribonucleic Acid Analysis as a Tool for the Diagnosis and Monitoring of Pediatric Solid Tumors.循环游离肿瘤脱氧核糖核酸分析作为小儿实体瘤诊断和监测的工具
Turk Arch Pediatr. 2023 May;58(3):241-249. doi: 10.5152/TurkArchPediatr.2023.23014.
10
Cancer incidence and surveillance strategies in individuals with RASopathies.RAS 相关疾病患者的癌症发病率和监测策略。
Am J Med Genet C Semin Med Genet. 2022 Dec;190(4):530-540. doi: 10.1002/ajmg.c.32018. Epub 2022 Dec 19.
无细胞游离 DNA 超低深度全基因组测序区分恶性外周神经鞘瘤(MPNST)与其良性前体病变:一项横断面研究。
PLoS Med. 2021 Aug 31;18(8):e1003734. doi: 10.1371/journal.pmed.1003734. eCollection 2021 Aug.
4
Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing.儿童基因组计划:全面 DNA 和 RNA 测序揭示儿科癌症中的致病性突变范围。
Cancer Discov. 2021 Dec 1;11(12):3008-3027. doi: 10.1158/2159-8290.CD-20-1631.
5
Neuroblastoma Molecular Risk-Stratification of DNA Copy Number and Genotyping via Cell-Free Circulating Tumor DNA Profiling.通过游离循环肿瘤DNA分析对神经母细胞瘤进行DNA拷贝数和基因分型的分子风险分层
Cancers (Basel). 2021 Jul 5;13(13):3365. doi: 10.3390/cancers13133365.
6
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.ctDNA 指导尿路上皮癌的辅助免疫治疗。
Nature. 2021 Jul;595(7867):432-437. doi: 10.1038/s41586-021-03642-9. Epub 2021 Jun 16.
7
Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden.基于游离 DNA 全基因组测序的多模态分析用于低突变负荷的儿科癌症。
Nat Commun. 2021 May 28;12(1):3230. doi: 10.1038/s41467-021-23445-w.
8
Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer.无细胞 DNA 可在预处理过的转移性癌症的快速尸检中捕获肿瘤异质性和驱动基因突变。
Nat Commun. 2021 May 27;12(1):3199. doi: 10.1038/s41467-021-23394-4.
9
Germline risk of clonal haematopoiesis.胚系造血细胞克隆性疾病风险
Nat Rev Genet. 2021 Sep;22(9):603-617. doi: 10.1038/s41576-021-00356-6. Epub 2021 May 13.
10
Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies.液体活检中游离 DNA 的表观遗传学、片段组学和拓扑结构。
Science. 2021 Apr 9;372(6538). doi: 10.1126/science.aaw3616.